Clinical Trial Update: Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma [Phase 1]

View source ↗

Summary

Phase I pharmacology study evaluating camptothecin-20-O-propionate hydrate (CZ48) in patients with advanced solid tumors or lymphomas; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• CZ48 (Camptothecin-20-O-propionate hydrate) (camptothecin-20-O-propionate hydrate)

Snippet

Sponsor: New Mexico Cancer Research Alliance | Conditions: Advanced Solid Tumors, Lymphomas | Phase 1 | Status: COMPLETED